LaineC.HortonR.DeAngelisC.D.Clinical trial registration-looking back and moving ahead. N Engl J Med.2007; 356: 2734–2736.
6.
ZarinD.A.TseT.IdeN.C.Trial registration at ClinicalTrials.gov between May and October 2005. N Engl J Med.2005; 353: 2779–2787.
7.
ICMJE: Journals that have requested inclusion on the list of publications that follow the ICMJE's uniform requirements for manuscripts submitted to biomedical journals.http://www.icmje.org/journals.html. Accessed August 9, 2013.
8.
ZarinD.A.TseT.WilliamsR.J.CaliffR.M.IdeN.C.The ClinicalTrials.gov results database — Update and key issues. N Engl J Med.2011; 364: 852–860.
9.
EarlyA.LauJ.UhligK.Haphazard reporting of deaths in clinical trials: A review of cases of ClinicalTrials.gov records and matched publications – A cross-sectional study. Br Med J Open.2013; 3: 001963.
10.
PrayleA.P.HurleyM.N.SmythA.R.Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: Cross-sectional study. Br Med J.2012; 344: d7373
11.
StockmannC.SherwinC.M.AmpofoK.Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.gov. Int J Antimircobial Agents.2013; 42(2): 161–166.
12.
CaliffR.M.ZarinD.A.KramerJ.M.ShermanR.E.AberleL.H.TasneemA.Characteristics of clinical trials registered in ClinicalTrials.gov, 2007–2010. JAMA.2012; 307(17): 1838–1847.
13.
RisingK.BacchettiP.BeroL.A.Reporting bias in drug trials submitted to the Food and Drug Administration: A review of presentation and publication. PLoS Med.2008; 5: e217. doi: 10.1371/journal.pmed.0050127
14.
LeeK.BacchettiP.SimI.Publication of clinical trials supporting successful new drug applications: A literature analysis. PLoS Med.2008; 5: e191. doi: 10.1371/journal.pmed.0050191
15.
NissenS.E.WolskiK.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med.2007; 356: 2457–2471.
16.
BennettC.L.SilverC.M.DjubelgovicB.Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer associated anemia. JAMA.2008; 299: 914–924.
17.
LawM.R.KawasumiY.MorganS.G.Despite law fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff.2011; 30(12): 2338–2345.
18.
GuyattG.H.OsmanA.D.VistG.E.GRADE working group. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. Br Med J.2008; 336(7650): 924–926.
19.
LeeD.H.VielemeyerO.Analysis of overall evidence behind Infectious Diseases Society of America Guidelines. Arch Intern Med.2011; 171(1): 18–22.
20.
MoherD.SchultzK.F.AltmanD.CONSORT group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA.2001; 285(15): 1987–1991.
21.
TricociP.AllenJ.M.KramerJ.M.CaliffR.M.SmithS.C.JrScientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA.2009; 301(8): 831–841.
22.
SteinbrookR.Public registration of clinical trials. New Engl J Med.2004; 351(4): 315–317.
23.
HuserV.CiminoJ.J.Evaluating adherence to the International Committee of Medical Journal Editor's policy of mandatory, timely clinical trial registration. J Am Med Inform Assoc.2013; 20: e169–e174.